A Pharmacodynamic Study of the P-glycoprotein Antagonist CBT-1 in Combination With Paclitaxel in Solid Tumors
The Oncologist, 04/26/2012Kelly RJ et al.
CBT–1 is able to inhibit Pgp–mediated efflux from PBMCs and normal liver to a degree observed with Pgp inhibitors studied in earlier clinical trials. Combined with its ease of administration and lack of toxicity, the data showing inhibition of normal tissue Pgp support further studies with CBT–1 to evaluate its ability to modulate drug uptake in tumor tissue.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.